NEPH Stock Analysis: Buy, Sell, or Hold?
NEPH - Nephros Inc.
$3.13
-0.21 (-6.29%)
▼
5d:
-11.08%
30d:
+6.1%
90d:
-23.66%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When NEPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NEPH is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NEPH is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NEPH is currently trading at $3.13, which is considered fair relative to its 30-day fair value range of $2.89 to $3.28. From a valuation perspective, the stock is trading at a premium (Forward PE: 31.3) compared to its historical average (27.3). At these levels, the market is pricing in 4.6% annual earnings growth.
Technical Outlook: Technically, NEPH is in a strong downtrend. Immediate support is located at $2.90, while resistance sits at $3.78. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: NEPH has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+123.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NEPH is in a strong downtrend. Immediate support is located at $2.90, while resistance sits at $3.78. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: NEPH has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+123.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.89 -
$3.28
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.9%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 123.6% below Wall St target ($7.00)
- BULLISH: Expecting earnings turnaround to 4.6% growth with 6.9% revenue growth
- WARNING: Recommendation downgraded due to -11.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.89 -
$3.28
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.90
Resistance Level
$3.78
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.30
Wall Street Target
$7.00
(+123.6%)
Revenue Growth (YoY)
6.9%
Earnings Growth (YoY)
-80.0%
Profit Margin
4.1%
Valuation Premium vs History
+4.6% premium
PE vs Historical
31.3 vs 27.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.6%
(market-implied from PE analysis)
1-Year Target
$3.27
(+5%)
2-Year Target
$3.42
(+9%)
3-Year Target
$3.58
(+14%)
3-Yr Target (if PE normalizes)
(PE: 31→27)
PE COMPRESSION
$3.12
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.3, Growth: 233.3%)
$10.56
(+238%)
Base:
(SPY PE: 22.1, Growth: 233.3%)
$7.45
(+138%)
Bear:
(PE: 18.8, Growth: 233.3%)
$6.33
(+102%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (48x PE), but valuation improves significantly next year (31x PE) as earnings recover.
Trailing PE: 47.71 | Current EPS (TTM): $0.07
Bull Case
$5.25
(+68%)
Analyst growth 42.9%, PE expands to 52.5
Base Case
$4.77
(+52%)
Market implied 42.9%, PE stable at 47.7
Bear Case
$2.27
(-27%)
Severe decline -20.0%, PE contracts to 40.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 18, 2026 5:55 AM ET
Data refreshes hourly during market hours. Next update: 6:55 AM
Data refreshes hourly during market hours. Next update: 6:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$577 | 58 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 53 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$271 | 59 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$179 | 49 HOLD |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$91 | 64 BUY |
